Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • University of Wisconsin • NCI-CCC Breast Tumor Board Question
What is the maximum cumulative anthracycline dose you would administer in a patient with metastatic breast cancer who is asymptomatic with good disease control on liposomal doxorubicin?
Answer from: Medical Oncologist at Academic Institution
The label states increased risk (11%) at a range of 450-550mg/m2, but some data from ovarian cancer patients demonstrated lower rates of CHF with prolonged use at up to 3x this exposure limit. (Safra et al., PMID 11038041) I had a metastatic patient who had a great response to doxil, so the joint de...
Sign in or Register to read more
Medical Oncologist
Fully agree. In the early days of HIV infection, the cutaneous manifestation, Kaposi’s sarcoma, was found to be very sensitive to liposomal doxorubicin. Patients were treated up to 1000 mg/m² without cardiac damage.